- Adalimumab biosimilars are as effective as the originator biologic for treating psoriasis.
- The study used data from the British Association of Dermatologists Biologics and Immunomodulators Register.
- Biosimilars offer potential cost savings and improved patient access to treatment.
- Further research with larger sample sizes is needed.
- Detailed baseline covariates should be considered to reduce bias.
Source: JAMA Dermatology
